These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23341582)

  • 1. Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis.
    Pehlivan Y; Kisacik B; Bosnak VK; Onat AM
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23341582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knee tuberculosis under rituximab therapy for rheumatoid arthritis.
    Ottaviani S; Tiendrebeogo J; Choudat L; Gill G; Palazzo E; Meyer O; Dieudé P
    Joint Bone Spine; 2013 Jul; 80(4):435-6. PubMed ID: 23238006
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis: When should we use rituximab to treat RA?
    Yazici Y
    Nat Rev Rheumatol; 2011 May; 7(7):379-80. PubMed ID: 21629243
    [No Abstract]   [Full Text] [Related]  

  • 7. [Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab].
    Braun MG; Wagener P
    Z Rheumatol; 2013 Mar; 72(2):166-71. PubMed ID: 23052405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.
    Slimani S; Lukas C; Combe B; Morel J
    Joint Bone Spine; 2011 Oct; 78(5):484-7. PubMed ID: 21196130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
    Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
    Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocardiosis in a patient with rheumatoid arthritis treated with rituximab and a summary of reported cases.
    Ngiu CS; Said MS; Periyasamy P; Low SF
    BMJ Case Rep; 2010 Sep; 2010():. PubMed ID: 22778377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.
    Gardette A; Ottaviani S; Tubach F; Roy C; Nicaise-Roland P; Palazzo E; Gill G; Meyer O; Dieudé P
    Joint Bone Spine; 2014 Oct; 81(5):416-20. PubMed ID: 24998790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.
    Rehnberg M; Brisslert M; Amu S; Zendjanchi K; Håwi G; Bokarewa MI
    Arthritis Res Ther; 2010; 12(3):R111. PubMed ID: 20529331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for the treatment of rheumatoid arthritis: an update.
    Mok CC
    Drug Des Devel Ther; 2013 Dec; 8():87-100. PubMed ID: 24403823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
    Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
    Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.